Former Genentech employee cuts plea deal with FBI in trade secrets case

A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Ex-DuPont employee gets 42 months over trade secret theft

24 December 2020 A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

article

Trade secrets: an alternative for life sciences IP?

9 July 2020 Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.

More on this story

Americas

Ex-DuPont employee gets 42 months over trade secret theft

24 December 2020 A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

article

Trade secrets: an alternative for life sciences IP?

More on this story

Americas

Ex-DuPont employee gets 42 months over trade secret theft

24 December 2020 A US federal appeals court has upheld a 42-month prison sentence for an ex-employee of DuPont Industrial Biosciences who stole trade secrets from the firm.

Big Pharma

Genentech to face revived Hemlibra claims

28 August 2020 Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.

article

Trade secrets: an alternative for life sciences IP?